(VIANEWS) – CONTEXTVISION (CONTX.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CONTEXTVISION (CONTX.OL) | kr8.00 | 3.49% | 61.1% |
| ESSILORLUXOTTICA (EL.PA) | €174.58 | 1.83% | 6.16% |
| UCB (UCB.BR) | €81.48 | 1.63% | 3.7% |
| BIOMERIEUX (BIM.PA) | €93.70 | 0.89% | 12.95% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CONTEXTVISION (CONTX.OL)
3.49% Forward Dividend Yield and 61.1% Return On Equity
ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and Rivent 3D, an image enhancement product for 3D ultrasound. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI. The company was founded in 1983 and is headquartered in Stockholm, Sweden.
Earnings Per Share
As for profitability, CONTEXTVISION has a trailing twelve months EPS of kr0.45.
PE Ratio
CONTEXTVISION has a trailing twelve months price to earnings ratio of 17.78. Meaning, the purchaser of the share is investing kr17.78 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.1%.
Yearly Top and Bottom Value
CONTEXTVISION’s stock is valued at kr8.00 at 02:30 EST, way under its 52-week high of kr10.46 and above its 52-week low of kr7.80.
More news about CONTEXTVISION.
2. ESSILORLUXOTTICA (EL.PA)
1.83% Forward Dividend Yield and 6.16% Return On Equity
EssilorLuxottica Société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in Europe, Middle East, Africa, Latin America, Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Crizal, Essilor, Eyezen, Stellest, Xperio, Optifog, Satisloh, Barberini, Shamir, Nikon, KODAK Lens, Oakley, OPTIFOG, Ray-Ban, Transitions, Vailux, and Xperio brands. It also provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Costa del Mar, Native Eyewear, Luxottica, Sferoflex, Heritage, Sensaya, Miki Ninn, DbyD, Unofficial and Seen, Arnette, Vogue Eyewear, Bolon, Molsion, and Ossé, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €4.84.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 36.07. Meaning, the purchaser of the share is investing €36.07 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
Volatility
ESSILORLUXOTTICA’s last week, last month’s, and last quarter’s current intraday variation average was 0.26%, 0.02%, and 1.10%.
ESSILORLUXOTTICA’s highest amplitude of average volatility was 1.07% (last week), 1.10% (last month), and 1.10% (last quarter).
Moving Average
ESSILORLUXOTTICA’s value is higher than its 50-day moving average of €172.42 and above its 200-day moving average of €171.51.
More news about ESSILORLUXOTTICA.
3. UCB (UCB.BR)
1.63% Forward Dividend Yield and 3.7% Return On Equity
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €2.15.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 37.9. Meaning, the purchaser of the share is investing €37.9 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.7%.
More news about UCB.
4. BIOMERIEUX (BIM.PA)
0.89% Forward Dividend Yield and 12.95% Return On Equity
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings Per Share
As for profitability, BIOMERIEUX has a trailing twelve months EPS of €3.82.
PE Ratio
BIOMERIEUX has a trailing twelve months price to earnings ratio of 24.53. Meaning, the purchaser of the share is investing €24.53 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.95%.
Moving Average
BIOMERIEUX’s value is higher than its 50-day moving average of €93.48 and under its 200-day moving average of €95.85.
Yearly Top and Bottom Value
BIOMERIEUX’s stock is valued at €93.70 at 02:30 EST, way under its 52-week high of €106.95 and way above its 52-week low of €77.48.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOMERIEUX’s stock is considered to be overbought (>=80).
More news about BIOMERIEUX.
